Quadria Capital, the Asia healthcare-focused private equity fund, is in advanced talks to acquire a significant minority stake in India's largest dialysis chain NephroPlus, valuing the latter at ₹2,000 crore ($250 million), said two sources aware of the development.Existing investors - the US-based Bessemer Venture Partners (BVP) and International Finance Corporation (IFC) - will exit fully by selling about 30% stake together, while the largest shareholder Investcorp is likely to sell a small stake in this round, said sources.

专注于亚洲医疗保健的私人股本基金Quadria Capital正在进行高级谈判，以收购印度最大透析连锁店NephroPlus的大量少数股权，后者的估值为₹2亿欧元（2.5亿美元），两位知情人士表示了解事态发展。消息人士称，现有投资者（总部位于美国的贝塞默风险投资合伙公司（BVP）和国际金融公司（IFC））将通过共同出售约30%的股权而完全退出，而最大股东Investcorp可能会在本轮出售少量股权。

Investcorp owns about 35-40% stake in NephroPlus. IIFL is another investor with 5-6% stake while promoters hold about 30% stake in NephroPlus.Founded in 2009 by Vikram Vuppala, Sandeep Gudibanda and Kamal Shah, NephroPlus operates 300 plus dialysis centres in more than 180 cities across four countries.

投资公司拥有NephroPlus约35-40%的股份。IIFL是另一家拥有5-6%股份的投资者，而发起人持有NephroPlus约30%的股份。NephroPlus由Vikram Vuppala、Sandeep Gudibanda和Kamal Shah于2009年成立，在四个国家的180多个城市运营着300多个透析中心。

NephroPlus treats 22,000 patients per month and has performed 8 million treatments to date.Existing investors started exploring their exit from NephroPlus at a valuation of ₹2,000 crore, ET first reported in October.Mails sent to Vuppala, CEO of NephroPlus, IFC, BVP, and Quadria spokespersons did not elicit any response, while Investcorp spokesperson declined to comment.

NephroPlus每月治疗22000名患者，迄今为止已进行了800万次治疗。现有投资者开始探索退出NephroPlus，估值为₹2000亿卢比，ET于10月首次报道。发给NephroPlus、IFC、BVP首席执行官Vuppala和Quadria发言人的邮件没有得到任何回应，而Investcorp发言人拒绝置评。

NephroPlus is expected to have an Ebitda of ₹90-100 crore in FY24, and the company may be valued at 20X Ebitda multiple, said sources.In 2021, NephroPlus raised $24 million (₹180 crore) as Series E funding round led by IIFL Asset Management (IIFL AMC), along with existing investors Investcorp and BVP.

NephroPlus预计息税折旧摊销前利润为₹消息人士称，该公司在2014财年的估值可能为息税折旧摊销前利润（Ebitda）的20倍。2021年，NephroPlus筹集了2400万美元(₹由IIFL资产管理公司（IIFL AMC）以及现有投资者Investcorp和BVP牵头的E轮融资（1.8亿欧元）。

Till date, NephroPlus has raised about $104 million through several rounds.In January 2023, NephroPlus received about ₹70 crore loan from Asian Development Bank to expand in Uzbekistan. NephroPlus is setting up four dialysis centres as part of a partnership with the ministry of health,.

迄今为止，NephroPlus已通过几轮融资筹集了约1.04亿美元。2023年1月，NephroPlus收到了大约₹亚洲开发银行向乌兹别克斯坦提供7000万欧元贷款。作为与卫生部合作的一部分，NephroPlus正在建立四个透析中心，。